How many drugs treat Keratitis?

Drug Landscape tracks 9 marketed treatments for Keratitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/keratitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Keratitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Keratitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Keratitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
Cortisporin	BACITRACIN	Pfizer	bacitracin	Tyrosine-protein kinase Lck	1948-01-01
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Keratitis
Generic (originally Merck) · 1 drug in Keratitis
Generic (originally Merck/Upjohn) · 1 drug in Keratitis
· 1 drug in Keratitis
Hannover Medical School · 1 drug in Keratitis
University of Zurich · 1 drug in Keratitis
Generic (originally Schering) · 1 drug in Keratitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Keratitis:

Cite this brief

Drug Landscape (2026). Keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/keratitis. Accessed 2026-06-10.

Keratitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing